Staphylococcus aureus Bacteremia Market Insights, Epidemiology, and Market Forecast 2030
(Albany, US) DelveInsight ha s launched a new report on Staphylococcus aureus Bacteremia Market
DelveInsight’s Staphylococcus aureus Bacteremia Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Staphylococcus aureus Bacteremia, historical and forecasted epidemiology as well as the Staphylococcus aureus Bacteremia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Staphylococcus aureus Bacteremia market report provides current treatment practices, emerging drugs, Staphylococcus aureus Bacteremia market share of the individual therapies, current and forecasted Staphylococcus aureus Bacteremia market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Staphylococcus aureus Bacteremia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Click Here For Sample Page:- https://www.delveinsight.com/sample-request/staphylococcus-aureus-bacteremia-market
Staphylococcus aureus Bacteremia Market Outlook
The Staphylococcus aureus Bacteremia market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Staphylococcus aureus Bacteremia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Staphylococcus aureus Bacteremia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Staphylococcus aureus Bacteremia market in 7MM is expected to change in the study period 2017-2030.
KEY FACT FROM THE REPORT
- S. aureus bacteremia is estimated with an incidence rate ranging from 20 to 50 cases per 100,000 population per year (Van Hal et al. 2012). Even though overall rates of SAB may have stabilized, the incidence of MRSA
bacteremia has increased dramatically in recent years in both the US and Europe. - In the study of 247 evaluable adult patients with S. aureus bacteremia, the episodes of bacteremia were classified according to acquisition type, in which 23.5% were nosocomial (N-SAB), 58.7% were healthcare-associated (HCA-SAB), and 17.8% were community-acquired (CA-SAB) (Atrouni et al., 2009).
- According to DelveInsight’s analysis, male gender is consistently associated with increased SAB incidence with male-to-female ratios of ∼1.5. The basis for this increased risk is not understood.
MAJOR KEY PLAYERS OF THE REPORT
- Basilea Pharmaceuticals
- NovaDigm Co.
- Intron Biotechnology
NAME OF DRUGS COVERED IN THE REPORT
- Oxacillin
- Ceftobiprole
- NDV-3A
Table of content
1. Key Insights
2. Executive Summary of Staphylococcus aureus Bacteremia
3. Competitive Intelligence Analysis for Staphylococcus aureus Bacteremia
4. Staphylococcus aureus Bacteremia: Market Overview at a Glance
4.1. Staphylococcus aureus Bacteremia Total Market Share (%) Distribution in 2017
4.2. Staphylococcus aureus Bacteremia Total Market Share (%) Distribution in 2030
5. Staphylococcus aureus Bacteremia: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Staphylococcus aureus Bacteremia Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Staphylococcus aureus Bacteremia Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Staphylococcus aureus Bacteremia Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Staphylococcus aureus Bacteremia Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Staphylococcus aureus Bacteremia Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Staphylococcus aureus Bacteremia Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Staphylococcus aureus Bacteremia Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Staphylococcus aureus Bacteremia Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Staphylococcus aureus Bacteremia Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Staphylococcus aureus Bacteremia Treatment and Management
8.2. Staphylococcus aureus Bacteremia Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Staphylococcus aureus Bacteremia Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
13. Staphylococcus aureus Bacteremia: Seven Major Market Analysis
13.1. Key Findings
13.2. Staphylococcus aureus Bacteremia Market Size in 7MM
13.3. Staphylococcus aureus Bacteremia Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Staphylococcus aureus Bacteremia Total Market Size in the United States
15.1.2. Staphylococcus aureus Bacteremia Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Staphylococcus aureus Bacteremia Total Market Size in Germany
15.3.2. Staphylococcus aureus Bacteremia Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Staphylococcus aureus Bacteremia Total Market Size in France
15.4.2. Staphylococcus aureus Bacteremia Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Staphylococcus aureus Bacteremia Total Market Size in Italy
15.5.2. Staphylococcus aureus Bacteremia Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Staphylococcus aureus Bacteremia Total Market Size in Spain
15.6.2. Staphylococcus aureus Bacteremia Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Staphylococcus aureus Bacteremia Total Market Size in the United Kingdom
15.7.2. Staphylococcus aureus Bacteremia Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Staphylococcus aureus Bacteremia Total Market Size in Japan
15.8.3. Staphylococcus aureus Bacteremia Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Staphylococcus aureus Bacteremia
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Related Reports
ABOUT DELVEINSIGHT
DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.
CONTACT US:
Shruti Thakur
[email protected]
+91-9650213330